131 related articles for article (PubMed ID: 3594716)
1. Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes.
Kim S; Kim DJ; Howell SB
Cancer Chemother Pharmacol; 1987; 19(4):307-10. PubMed ID: 3594716
[TBL] [Abstract][Full Text] [Related]
2. Multivesicular liposomes containing cytarabine entrapped in the presence of hydrochloric acid for intracavitary chemotherapy.
Kim S; Howell SB
Cancer Treat Rep; 1987; 71(7-8):705-11. PubMed ID: 3607782
[TBL] [Abstract][Full Text] [Related]
3. The treatment of intravenously implanted Lewis lung carcinoma with two sustained release forms of 1-beta-D-arabinofuranosylcytosine.
Rahman YE; Patel KR; Cerny EA; Maccoss M
Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1105-12. PubMed ID: 6540691
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate.
Hashida M; Kojima T; Muranishi S; Sezaki H
Gan; 1978 Dec; 69(6):839-43. PubMed ID: 750275
[TBL] [Abstract][Full Text] [Related]
6. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
Rubas W; Supersaxo A; Weder HG; Hartmann HR; Hengartner H; Schott H; Schwendener R
Int J Cancer; 1986 Jan; 37(1):149-54. PubMed ID: 3941019
[TBL] [Abstract][Full Text] [Related]
7. Comparison of lymphatic uptake, metabolism, excretion, and biodistribution of free and liposome-entrapped [14C]cytosine beta-D-arabinofuranoside following intraperitoneal administration to rats.
Parker RJ; Priester ER; Sieber SM
Drug Metab Dispos; 1982; 10(1):40-6. PubMed ID: 6124381
[TBL] [Abstract][Full Text] [Related]
8. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
Allen TM; Mehra T; Hansen C; Chin YC
Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213
[TBL] [Abstract][Full Text] [Related]
9. [Influencing factors in the leakage of liposome and arabinoside cytosine (ARA-C) entrapped in liposomes in treatment of L1210 mouse leukemia].
Fu NW
Zhonghua Zhong Liu Za Zhi; 1985 Jul; 7(4):250-3. PubMed ID: 4085312
[TBL] [Abstract][Full Text] [Related]
10. Multivesicular liposomes containing cytarabine for slow-release Sc administration.
Kim S; Howell SB
Cancer Treat Rep; 1987 May; 71(5):447-50. PubMed ID: 3567968
[TBL] [Abstract][Full Text] [Related]
11. Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model.
Grem JL; Plowman J; Rubinstein L; Hawkins MJ; Harrison SD
Leuk Res; 1991; 15(4):229-36. PubMed ID: 2030604
[TBL] [Abstract][Full Text] [Related]
12. Retention of cytosine arabinoside in mouse lung following intravenous administration in liposomes of different size.
Hunt CA; Rustum YM; Mayhew E; Papahadjopoulos D
Drug Metab Dispos; 1979; 7(3):124-8. PubMed ID: 38080
[TBL] [Abstract][Full Text] [Related]
13. Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C).
Breithaupt H; Pralle H; Eckhardt T; von Hattingberg M; Schick J; Löffler H
Cancer; 1982 Oct; 50(7):1248-57. PubMed ID: 7104969
[TBL] [Abstract][Full Text] [Related]
14. [Liposomes as carriers of lipophilic cytosine arabinoside and fluorodeoxyuridine derivatives. Their cytostatic effect and possibilities of tumor cell specific therapy].
Schwendener RA; Schott H; Hartmann HR; Supersaxo A; Rubas W; Hengartner H
Onkologie; 1987 Aug; 10(4):232-9. PubMed ID: 2959889
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma.
King ME; Pfeifle CE; Howell SB
J Clin Oncol; 1984 Jun; 2(6):662-9. PubMed ID: 6726304
[TBL] [Abstract][Full Text] [Related]
16. Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes.
Mayhew E; Rustum YM; Szoka F; Papahadjopoulos D
Cancer Treat Rep; 1979; 63(11-12):1923-8. PubMed ID: 526925
[No Abstract] [Full Text] [Related]
17. Organ-selective action of an antitumor drug: pharmacologic studies of liposome-encapsulated beta-cytosine arabinoside administered via the respiratory system of the rat.
McCullough HN; Juliano RL
J Natl Cancer Inst; 1979 Sep; 63(3):727-31. PubMed ID: 288932
[TBL] [Abstract][Full Text] [Related]
18. Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia.
Yang JL; Cheng EH; Capizzi RL; Cheng YC; Kute T
J Clin Invest; 1985 Jan; 75(1):141-6. PubMed ID: 4038404
[TBL] [Abstract][Full Text] [Related]
19. Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo.
Ganapathi R; Krishan A; Wodinsky I; Zubrod CG; Lesko LJ
Cancer Res; 1980 Mar; 40(3):630-3. PubMed ID: 7471083
[TBL] [Abstract][Full Text] [Related]
20. High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides.
Sinkule JA; Evans WE
J Chromatogr; 1983 May; 274():87-93. PubMed ID: 6575975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
